Sana Biotechnology, Inc. Stockholder News: Robbins LLP Reminds Investors of the Class Action Lawsuit Against SANA

Core Viewpoint - A class action lawsuit has been filed against Sana Biotechnology, Inc. for allegedly misleading investors regarding its financial stability and the potential of its product candidates [1][2]. Group 1: Allegations Against Sana Biotechnology - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain operations and advance its product candidates [2]. - Specific product candidates, including SC291 in oncology, SC379, and SG299, were reportedly less promising than what the company had communicated to investors [2]. - To conserve cash and focus on more promising candidates, Sana was likely to reduce funding for or discontinue certain projects and significantly cut its workforce [2]. - As a result, the company allegedly overstated its financial capacity to sustain operations and advance its product pipeline [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by May 20, 2025 [3]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3]. Group 3: About Robbins LLP - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4].